Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains

Oncogenesis

Volumn 5, Issue 5, 2016, Pages

  Michael, J V ^a   Wurtzel, J G T ^a   Goldfinger, L E ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991786384     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/ONCSIS.2016.36     Document Type: Article

References (68)

1. Adjei A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062–1074.
2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11–22.
3. Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes and Cancer 2011; 2: 344–359.
4. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997; 11: 2468–2481.
5. Cheng CM, Li H, Gasman S, Huang J, Schiff R, Chang EC. Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies. Mol Cell Biol 2010; 31: 983–997.
6. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761–774.
7. Berrier AL, Mastrangelo AM, Downward J, Ginsberg M, LaFlamme SE. Activated R-ras, Rac1, PI 3-kinase and PKCepsilon can each restore cell spreading inhibited by isolated integrin beta1 cytoplasmic domains. J Cell Biol 2000; 151: 1549–1560.
8. Conklin MW, Ada-Nguema A, Parsons M, Riching KM, Keely PJ. R-Ras regulates beta1-integrin trafficking via effects on membrane ruffling and endocytosis. BMC Cell Biol 2010; 11: 14.
9. Keely PJ, Rusyn EV, Cox AD, Parise LV. R-Ras signals through specific integrin alpha cytoplasmic domains to promote migration and invasion of breast epithelial cells. J Cell Biol 1999; 145: 1077–1088.
10. Kwong L, Wozniak MA, Collins AS, Wilson SD, Keely PJ. R-Ras promotes focal adhesion formation through focal adhesion kinase and p130(Cas) by a novel mechanism that differs from integrins. Mol Cell Biol 2003; 23: 933–949.
11. Sethi T, Ginsberg MH, Downward J, Hughes PE. The small GTP-binding protein R-Ras can influence integrin activation by antagonizing a Ras/Raf initiated integrin suppression pathway. Mol Biol Cell 1999; 10: 1799–1809.
12. Wurtzel JG, Kumar P, Goldfinger LE. Palmitoylation regulates vesicular trafficking of R-Ras to membrane ruffles and effects on ruffling and cell spreading. Small GTPases 2012; 3: 139–153.
13. Cox AD, Brtva TR, Lowe DG, Der CJ. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells. Oncogene 1994; 9: 3281–3288.
14. Saez R, Chan AM, Miki T, Aaronson SA. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes. Oncogene 1994; 9: 2977–2982.
15. Holly SP, Larson MK, Parise LV. The unique N-terminus of R-ras is required for Rac activation and precise regulation of cell migration. Mol Biol Cell 2005; 16: 2458–2469.
16. Moodie S, Willumsen BM, Weber MJ, Wolfman A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993; 260: 1658–1661.
17. Morrison D, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997; 9: 174–179.
18. Van Aelst L, Barr M, Marcus S, Polverino A, Wigler M. Complex formation between RAS and RAF and other protein kinases. Proc Natl Acad Sci USA 1993; 90: 6213–6217.
19. Marte BM, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr Biol 1997; 7: 63–70.
20. Spaargaren M, Martin GA, McCormick F, Fernandez-Sarabia MJ, Bischoff JR. The Ras-related protein R-ras interacts directly with Raf-1 in a GTP-dependent manner. Biochem J 1994; 300: 303–307.
21. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 2012; 13: 39–51.
22. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 1990; 63: 133–139.
23. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989; 57: 1167–1177.
24. Schmittberger T, Waldmann H. Synthesis of the palmitoylated and prenylated C-terminal lipopeptides of the human R-and N-Ras proteins. Bioorg Med Chem 1999; 7: 749–762.
25. Baumgart F, Corral-Escariz M, Perez-Gil J, Rodriguez-Crespo I. Palmitoylation of R-Ras by human DHHC19, a palmitoyl transferase with a CaaX box. Biochim Biophys Acta 2010; 1798: 592–604.
26. Swarthout JT, Lobo S, Farh L, Croke MR, Greentree WK, Deschenes RJ et al. DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H-and N-Ras. J Biol Chem 2005; 280: 31141–31148.
27. Ahearn IM, Tsai FD, Court H, Zhou M, Jennings BC, Ahmed M et al. FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol Cell 2011; 41: 173–185.
28. Apolloni A, Prior IA, Lindsay M, Parton RG, Hancock JF. H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol Cell Biol 2000; 20: 2475–2487.
29. Goodwin JS, Drake KR, Rogers C, Wright L, Lippincott-Schwartz J, Philips MR et al. Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway. J Cell Biol 2005; 170: 261–272.
30. Misaki R, Morimatsu M, Uemura T, Waguri S, Miyoshi E, Taniguchi N et al. Palmitoylated Ras proteins traffic through recycling endosomes to the plasma membrane during exocytosis. J Cell Biol 2010; 191: 23–29.
31. Rocks O, Peyker A, Kahms M, Verveer PJ, Koerner C, Lumbierres M et al. An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 2005; 307: 1746–1752.
32. Agudo-Ibanez L, Herrero A, Barbacid M, Crespo P. H-ras distribution and signaling in plasma membrane microdomains are regulated by acylation and deacylation events. Mol Cell Biol 2015; 35: 1898–1914.
33. Eisenberg S, Laude AJ, Beckett AJ, Mageean CJ, Aran V, Hernandez-Valladares M et al. The role of palmitoylation in regulating Ras localization and function. Biochem Soc Trans 2013; 41: 79–83.
34. Janosi L, Li Z, Hancock JF, Gorfe AA. Organization, dynamics, and segregation of Ras nanoclusters in membrane domains. Proc Natl Acad Sci USA 2012; 109: 8097–8102.
35. Matallanas D, Arozarena I, Berciano MT, Aaronson David S, Pellicer A, Lafarga M et al. Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J Biol Chem 2002; 278: 4572–4581.
36. Prior IA, Harding A, Yan J, Sluimer J, Parton RG, Hancock JF. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat Cell Biol 2001; 3: 368–375.
37. Hansen M, Prior IA, Hughes PE, Oertli B, Chou FL, Willumsen BM et al. C-terminal sequences in R-Ras are involved in integrin regulation and in plasma membrane microdomain distribution. Biochem Biophys Res Commun 2003; 311: 829–838.
38. Hansen M, Rusyn EV, Hughes PE, Ginsberg MH, Cox AD, Willumsen BM. R-Ras C-terminal sequences are sufficient to confer R-Ras specificity to H-Ras. Oncogene 2002; 21: 4448–4461.
39. Jaumot M, Yan J, Clyde-Smith J, Sluimer J, Hancock JF. The linker domain of the Ha-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase. J Biol Chem 2002; 277: 272–278.
40. Parton RG, Hancock JF. Caveolin and Ras function. Methods Enzymol 2001; 333: 172–183.
41. Self AJ, Paterson HF, Hall A. Different structural organization of Ras and Rho effector domains. Oncogene 1993; 8: 655–661.
42. Lee S, Wurtzel JG, Singhal SS, Awasthi S, Goldfinger LE. RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization. Cancer Res 2012; 72: 5165–5173.
43. Huff SY, Quilliam LA, Cox AD, Der CJ. R-Ras is regulated by activators and effectors distinct from those that control Ras function. Oncogene 1997; 14: 133–143.
44. Rey I, Taylor-Harris P, van Erp H, Hall A. R-ras interacts with rasGAP, neurofibromin, and c-raf but does not regulate cell growth or differentiation. Oncogene 1994; 9: 685–692.
45. Cole AL, Subbanagounder G, Mukhopadhyay S, Berliner JA, Vora DK. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway. Arterioscler Thromb Vasc Biol 2003; 23: 1384–1390.
46. Furuhjelm J, Peranen J. The C-terminal end of R-Ras contains a focal adhesion targeting signal. J Cell Sci 2003; 116: 3729–3738.
47. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004; 24: 4943–4954.
48. Self AJ, Caron E, Paterson HF, Hall A. Analysis of R-Ras signalling pathways. JCell Sci 2001; 114: 1357–1366.
49. Matallanas D, Sanz-Moreno V, Arozarena I, Calvo F, Agudo-Ibanez L, Santos E et al. Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation. Mol Cell Biol 2006; 26: 100–116.
50. Kapoor S, Weise K, Erlkamp M, Triola G, Waldmann H, Winter R. The role of G-domain orientation and nucleotide state on the Ras isoform-specific membrane interaction. Euro Biophys J 2012; 41: 801–813.
51. Mazhab-Jafari MT, Marshall CB, Smith MJ, Gasmi-Seabrook GM, Stathopulos PB, Inagaki F et al. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site. Proc Natl Acad Sci USA 2015; 112: 6625–6630.
52. Dent P, Haser W, Haystead TA, Vincent LA, Roberts TM, Sturgill TW. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 1992; 257: 1404–1407.
53. Kyriakis J, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR et al. Raf-1 activates MAP kinase-kinase. Nature 1992; 358: 417–421.
54. Leevers S, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994; 369: 411–414.
55. Oikonomou E, Koustas E, Goulielmaki M, Pintzas A. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 2014; 5: 11752–11777.
56. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994; 264: 1469–1467.
57. Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014; 120: 3446–3456.
58. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007; 129: 957–968.
59. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005; 7: 533–545.
60. Fruman D, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140–156.
61. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/AKT pathway in cancer. Oncogene 2008; 27: 5511–5526.
62. Lim HJ, Crowe P, Yang JL. Current clinical regulation of PI3K/PTEN/AKT/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol 2015; 141: 671–689.
63. Miller T, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011; 13: 224.
64. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol 2011; 6: 49–69.
65. Lynch T, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139.
66. Paez J, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500.
67. Silver L, Michael JV, Goldfinger LE, Gallo G. Activation of PI3K and R-ras signaling promotes the extension of sensory axons on inhibitory chondroitin sulfate proteoglycans. Dev Neurobiol 2014; 74: 918–933.
68. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 2008; 18: 56–62.